- PLATFORM
- Why Simsen
An ultra-sensitive ctDNA platform that fits how you actually work.
Detect signal at parts-per-million in samples your current platform calls negative. Run it as a service from our EU-accredited lab, or bring SiMSen-Seq in-house on your own instruments. Same chemistry, same sensitivity, your decision on delivery.
✓ ISO 15189 compliant · Open pipeline, raw data access · EU-based
Five things you cannot buy off the shelf elsewhere.
01
Sensitivity
You detect signal at parts-per-million, in samples your current platform may call negative.
02
Flexibility
You choose: send samples to our accredited lab, or run SiMSen-Seq on your own instruments.
03
Clinical insight
You see actionable variants and tumour evolution, not just a binary positive or negative.
04
Transparency
You get full raw data access and an open analysis pipeline. Your bioinformatics team can verify, reanalyse or extend our results with their own tools.
05
Partnership
You work with a specialist team: co-publication, protocol design and interpretation help.
Read the platform in whichever order serves you.
Each of the four pages below is written for a different visitor. Start where you are. Each takes about three minutes to read.
———
01 / Why Simsen
The five reasons people choose us.
If you are deciding whether to talk to us at all.
The five benefit-framed pillars that run through everything: sensitivity, flexibility, clinical insight , transparency partnership. The shortest route to whether we are worth a conversation.
———
02 / Technology
The science under the hood.
If you already understand ctDNA and want the details.
Barcoded duplex sequencing, error suppression, validated sensitivity down to single molecules. Performance data, the sample-to-result workflow, and the limitations we are open about.
———
01 / Why Simsen
The five reasons people choose us.
If you are deciding whether to talk to us at all.
The five benefit-framed pillars that run through everything: sensitivity, flexibility, clinical insight , transparency partnership. The shortest route to whether we are worth a conversation.
———
02 / Technology
The science under the hood.
If you already understand ctDNA and want the details.
Barcoded duplex sequencing, error suppression, validated sensitivity down to single molecules. Performance data, the sample-to-result workflow, and the limitations we are open about.
TRUSTED BY LEADING EUROPEAN CLINICS, HOSPITALS AND BIOTECHS
Performance in numbers, from the work already done.
|
<0.001% |
9 months |
3-5 ppm |
| Variant allele frequency you can detect, in your own samples. Single molecules, separated from background error. | Earlier than imaging picked up relapse, in paediatric sarcoma monitoring. |
Residual ctDNA you can see three days after pancreatic surgery, in samples other platforms would have called clean. |
| SIMSEN-SEQ, NATURE PROTOCOLS → | EK ET AL., 2024 → | PRELIMINARY, STUDY ONGOING → |
Three audiences. One platform. Three different conversations.
The platform is the same; what it means for you depends on which side of the bench, the trial protocol or the patient chart you are sitting on.
———
For clinical trials
Validate MRD endpoints. Move faster.
Design ctDNA endpoints into your European oncology trial, with raw data access and co-publication built in.
———
For research and laboratories
See signals others miss.
Send samples, for the hardest cases, or bring SiMSen-Seq in-house on your own instruments with LabSuite.
———
For clinics
Catch relapse before imaging does.
Personalised ctDNA monitoring for your oncology patients, with EU logistics and time-zone-aligned support.
Speak to our scientific team.
A real human, in CET/CEST time zone, who has run samples like yours.